Greenwich LifeSciences Inc Ordinary Shares GLSI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $23.88
- Day Range
- $23.99–25.50
- 52-Week Range
- $7.78–34.10
- Bid/Ask
- $24.00 / $24.65
- Shares Outstanding
- 14.67M
- Market Cap
- $352.13M
- Volume/Avg
- 110,671 / 150,258
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 13
Valuation
|
Metric
|
GLSI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 66.95 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
GLSI
|
|---|---|
Quick Ratio | 2.01 |
Current Ratio | 2.01 |
Interest Coverage | — |
Quick Ratio
GLSI
Profitability
|
Metric
|
GLSI
|
|---|---|
Return on Assets (Normalized) | −283.57% |
Return on Equity (Normalized) | −708.02% |
Return on Invested Capital (Normalized) | −714.38% |
Return on Assets
GLSI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Affymax Inc
AFFY
| — | Zcdtf | — | |||
| Athersys Inc
ATHXQ
| — | Rxc | — | |||
| Vertex Pharmaceuticals Inc
VRTX
| Ycpmmzdg | Klqrs | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fjghyjc | Swnqtm | $64B | |||
| UCB SA
UCBJF
| — | Zxmc | $61B | |||
| UCB SA ADR
UCBJY
| — | Ctjx | $61B | |||
| argenx SE
ARGNF
| — | Pkgyf | $56B | |||
| argenx SE ADR
ARGX
| Gyxkwjzl | Wfc | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Tpjkpcv | Lvdqqq | $38B | |||
| CSL Ltd
CMXHF
| — | Ybrkzp | $36B |
United States